Effect on stroke of different progestagens in low oestrogen dose oral contraceptives

Poulter, N.R.; Chang, C.L.; Farley, T.M.M.; Marmot, M.G.; Meirik, O.; Who Collaborative Study, O.C.rdiovascular Disease And Steroid Hormone Contraception; Poulter, N.R; Chang, C.L; Farley, T.M.M; Marmot, M.G; Meirik, O; Who Collaborative Study, O.C.rdiovascular Disease And Steroid Hormone Contraceptio

doi:10.1016/s0140-6736(99)01013-2

Home

>

Node

>

Subnode

Effect on stroke of different progestagens in low oestrogen dose oral contraceptives

Poulter, N.R.; Chang, C.L.; Farley, T.M.M.; Marmot, M.G.; Meirik, O.; Who Collaborative Study, O.C.rdiovascular Disease And Steroid Hormone Contraception

Lancet (North American Edition) 354(9175): 301-302

1999

ISSN/ISBN: 0140-6736

DOI: 10.1016/s0140-6736(99)01013-2

Document Number: 510744

The multicentre WHO collaborative case-control study had limited power to differentiate stroke risks by progestagen component in low dose combined oral contraceptives. Given this caveat, odds ratios for ischaemic, haemorrhagic, and all strokes combined associated with use of oral contraceptives containing desogestrel or gestodene ("third generation") were found to be similar to those containing levonorgestrel in this study.